Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE AND LUOXIN PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION ON AI-POWERED DRUG DISCOVERY FOR DIGESTIVE, METABOLIC AND OTHER CHRONIC DISEASES

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Insilico Medicine Ltd.* (英矽智能科技(上海)有限公司), a wholly-owned subsidiary of the Company, has recently entered into a strategic cooperation agreement (the "**Strategic Cooperation Agreement**") with Luoxin Pharmaceuticals Group Stock Co., Ltd.* (羅欣藥業集團股份有限公司) ("**Luoxin Pharmaceuticals**", SZSE: 002793).

Under the Strategic Cooperation Agreement, the parties intend to establish a long-term strategic partnership focused on innovative drug research and development ("**R&D**"), advancing the in-depth integration of artificial intelligence with disease-area expertise, research data and R&D experience, and jointly exploring innovative drug R&D with clinical value and development potential. The parties will prioritize digestive system diseases, metabolic diseases and other non-oncology chronic diseases, and will gradually expand their collaboration into additional disease areas as the collaboration progresses and as mutually agreed.

The parties will advance their collaboration based on the principles of "joint assessment, phased implementation, and project-by-project confirmation". By leveraging their respective resource strengths, technical foundations, and channel capabilities, the parties aim to complement each other's advantages, achieve synergistic development, further enhance the Company's core competitiveness, and support its long-term strategic development. The scope of cooperation includes disease research and target discovery, innovative molecule discovery and optimization, support for ongoing pipeline programs, translational R&D and related collaboration, technical and professional exchanges, and other mutually agreed areas.

The Strategic Cooperation Agreement merely represents a strategic consensus reached between the parties for carrying out the cooperation. The specific details of the cooperation remain subject to further negotiation and determination, and the specific cooperation arrangements shall be governed by the definitive agreement(s) and other formal transaction documents to be eventually executed. There remains uncertainty as to the subsequent progress of the cooperation.

Forward-looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement have also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, November 13, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.

* *For identification purposes only*